公开(公告)号：US20240269284A1

公开(公告)日：2024-08-15

申请号：US18565831

申请日：2022-06-01

申请人： H. Lee Moffitt Cancer Center and Research Institute Inc. ,  Regents of the University of Minnesota

发明人： Marco Davila ,  Brian Betts

IPC分类号： A61K39/00 ,  A61K38/20

CPC分类号： A61K39/46433 ,  A61K38/2013 ,  A61K39/4611 ,  A61K39/4631

摘要： Particular interest has arisen regarding the therapeutic potential of regulatory T cells (Tregs) in ischemic stroke. However, the ex vivo-expansion of Tregs usually takes several weeks to achieve a target number of cells. Allogeneic (off-the-shelf) Tregs would be desirable, but are limited by acute graft-versus-host disease (GVHD). As disclosed herein, CD83 is differentially expressed on alloreactive T cells. Therefore, disclosed herein are immune effector cells genetically modified to express a chimeric antigen receptor (CAR) polypeptide targeting CD83 that are capable of suppressing this alloreactivity. In some embodiments, the immune effector cell is used in combination with an autologous Treg therapy. In other embodiments, the autologous Treg is itself genetically modified to express the CAR polypeptide targeting CD83.

公开(公告)号：US20230302133A1

公开(公告)日：2023-09-28

申请号：US18020611

申请日：2021-08-24

申请人： The Regents of the University of California

发明人： Andrew H. Ng ,  Matthew Kim

IPC分类号： A61K39/00 ,  A61K38/17 ,  C12N5/0783

CPC分类号： A61K39/4631 ,  A61K39/4611 ,  A61K39/46433 ,  A61K38/1709 ,  C12N5/0636

摘要： Described herein is a therapeutic cell that expresses a fusion protein comprising: (a) a target-binding domain; and (b) a degradation domain, e.g., a degron or E3 ligase-recruiting domain, that is heterologous to the target-binding domain. In the therapeutic cell, binding of the fusion protein to a target protein via the target-binding domain induces degradation of the target protein. The therapeutic cell can be an immunostimulatory cell, an immunoinhibitory cell or a stem cell, for example. Methods of treatment using the cell are also provided.

公开(公告)号：US20230287097A1

公开(公告)日：2023-09-14

申请号：US18005669

申请日：2021-07-15

申请人： PORTON BIOLOGICS LTD

发明人： Lingjie KONG ,  Jean WANG ,  Tianwei GUO ,  Shicheng ZHU ,  Ying CHEN

IPC分类号： C07K16/24 ,  C07K14/705 ,  C07K14/725 ,  A61K39/395 ,  A61K38/17 ,  A61K39/00

CPC分类号： C07K16/241 ,  C07K14/70517 ,  C07K14/70578 ,  C07K14/7051 ,  A61K39/3955 ,  A61K38/1774 ,  A61K38/177 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/46433 ,  A61K2039/505 ,  C07K2319/33 ,  C07K2319/03 ,  C07K2319/02 ,  C07K2317/622 ,  C07K2317/21 ,  C07K2317/24 ,  A61K2239/13 ,  A61K2239/17 ,  A61K2239/21 ,  A61K2239/22

摘要： Provided a chimeric anti-drug antibody receptor (CADAR) specific for anti-drug-antibody-based B cell receptor (BCR), the anti-drug antibody is induced by a therapeutic anti-TNF-alpha monoclonal antibody. Also provided compositions comprising the CADAR, polynucleotides encoding the CADAR, vectors comprising a polynucleotide encoding the CADAR, engineered cells comprising the CADAR, and method using the same.

公开(公告)号：US20240226297A9

公开(公告)日：2024-07-11

申请号：US18548481

申请日：2022-03-01

申请人： THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

发明人： James L. Riley ,  Gavin Ellis

IPC分类号： A61K39/00 ,  C07K14/705 ,  C07K14/725 ,  C07K16/40

CPC分类号： A61K39/46433 ,  A61K39/4611 ,  A61K39/4631 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K16/40 ,  C07K2317/22 ,  C07K2317/569 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/33

摘要： The present invention includes compositions and methods for an DPP6 specific chimeric antigen receptor (CAR). In certain embodiments the DPP6 specific CAR is expressed on a T regulatory cell. In certain embodiments, the DPP6 specific CAR is used to treat type 1 diabetes.

公开(公告)号：US12006364B2

公开(公告)日：2024-06-11

申请号：US17588427

申请日：2022-01-31

申请人： Vaccinex, Inc.

发明人： Ernest S. Smith ,  Terrence Lee Fisher

IPC分类号： A61K39/00 ,  A61K38/17 ,  A61K39/395 ,  A61K45/06 ,  A61P25/00 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30

CPC分类号： C07K16/2803 ,  A61K38/1774 ,  A61K39/0001 ,  A61K39/3955 ,  A61K39/39558 ,  A61K39/4611 ,  A61K39/46433 ,  A61K45/06 ,  A61P25/00 ,  C07K16/18 ,  C07K16/2896 ,  C07K16/30 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

摘要： Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CD100 monoclonal antibodies have been developed to neutralize CD100.

公开(公告)号：US20240173406A1

公开(公告)日：2024-05-30

申请号：US18284701

申请日：2022-04-01

申请人： NUTCRACKER THERAPEUTICS, INC.

发明人： Samuel Deutsch ,  Ole Haabeth

IPC分类号： A61K39/00 ,  C12N5/0783

CPC分类号： A61K39/4611 ,  A61K39/0011 ,  A61K39/46433 ,  A61K39/464499 ,  C12N5/0636 ,  A61K2039/53 ,  A61K2039/55555

摘要： The disclosure provides materials in the form of nanoparticles containing in vitro-transcribed mRNAs encoding antigenic peptides and personalized medicine methods for treating or preventing diseases such as cancer, an autoimmune disease, an infectious disease, or inflammation, wherein cells of a subject receiving prophylactic or therapeutic treatment are brought into contact with the nanoparticles ex vivo, and the subject's cells process the mRNA. expressing and presenting the encoded product to activate the subject's own T cells. thereby mounting an immune response to the diseased cells. such as cancer cells.

公开(公告)号：US20240150472A1

公开(公告)日：2024-05-09

申请号：US18550610

申请日：2022-03-16

申请人： Daiichi Sankyo Company, Limited

发明人： Kazunori Yoshikiyo ,  Kazumichi Goto ,  Maki Tsujimoto ,  Chikako Nagasaki ,  Sayaka Yoshida ,  Hiroaki Tagaya

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61P21/04 ,  C07K14/705 ,  C07K14/725 ,  C12N15/86

CPC分类号： C07K16/286 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/46433 ,  A61P21/04 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70571 ,  C12N15/86 ,  C07K2319/02 ,  C07K2319/03 ,  C12N2740/15043

摘要： The present invention provides a chimeric polypeptide receptor in which an extracellular region comprising an antigenic region capable of being bound by an anti-human nicotinic acetylcholine receptor α1 subunit (nAChRα1) antibody, a transmembrane region, and an intracellular domain comprising an intracellular signaling domain are arranged in the presented order from the N-terminus towards the C-terminus, wherein an amino acid sequence of the antigenic region comprises the amino acid sequence as set forth in SEQ ID NO: 2 or an amino acid sequence derived from the amino acid sequence as set forth in SEQ ID NO: 2 by the substitution, deletion, insertion, and/or addition of one or several amino acids, a polynucleotide encoding the chimeric polypeptide receptor polypeptide, a cell expressing the chimeric polypeptide receptor, etc., which are useful in the treatment of myasthenia gravis.

公开(公告)号：US20240350630A1

公开(公告)日：2024-10-24

申请号：US18583233

申请日：2024-02-21

申请人： AstraZeneca AB

发明人： Jessica Gayle Tong ,  Deepali Malhotra ,  Michael Overstreet ,  Gordon Moody ,  Mark Cobbold ,  Laura Vian ,  Gianluca Carlesso ,  Attilio Bondanza ,  Ryan Nicholas Gilbreth

IPC分类号： A61K39/00 ,  A61P35/00 ,  A61P37/06 ,  C07K14/705 ,  C07K14/715 ,  C07K14/725 ,  C07K14/73 ,  C07K16/28

CPC分类号： A61K39/46433 ,  A61K39/4631 ,  A61P35/00 ,  A61P37/06 ,  C07K14/70507 ,  C07K14/7051 ,  C07K14/70514 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70578 ,  C07K14/7155 ,  C07K16/2878 ,  C07K2319/03

摘要： This disclosure relates to compositions and methods for treating disease using chimeric antigen receptor cells and/or antigen binding domains targeting BCMA.

公开(公告)号：US20240307538A1

公开(公告)日：2024-09-19

申请号：US18551156

申请日：2022-03-18

申请人： UNIVERSITE TOULOUSE III - PAUL SABATIER ,  INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE ,  CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER ,  UNIVERSITE DE MONTPELLIER ,  ARTHRITIS RECHERCHE & DEVELOPPEMENT

发明人： Cyril CLAVEL ,  Guy Bruno René SERRE ,  Pierre MARTINEAU ,  Nerea ALLENDE-VEGA ,  Florence APPARAILLY ,  Martin VILLALBA ,  Christian JORGENSEN

IPC分类号： A61K39/00 ,  C07K14/735 ,  C07K14/75 ,  C12N5/0783 ,  C12N5/0786

CPC分类号： A61K39/46433 ,  A61K39/4613 ,  A61K39/4614 ,  A61K39/4621 ,  C07K14/70535 ,  C07K14/75 ,  C12N5/0645 ,  C12N5/0646 ,  C07K2319/30 ,  C12N2510/00

摘要： The invention relates to an immune cell comprising at least one Fc receptor on its surface, characterised in that a hybrid molecule is grafted onto the Fc receptor, said hybrid molecule comprising at least one antibody Fc fragment covalently bound to at least one fibrin-derived peptide comprising one or more citrullyl residue(s). The present invention also relates to the uses of such a grafted cell, as well as its method of production.

公开(公告)号：US20240261405A1

公开(公告)日：2024-08-08

申请号：US18329959

申请日：2023-06-06

申请人： Kyverna Therapeutics, Inc.

发明人： John Lee ,  Lih-Yun Hsu ,  Jeffrey Greve

IPC分类号： A61K39/00 ,  A61P37/06 ,  C07K14/705 ,  C07K14/715 ,  C07K14/725 ,  C07K16/28 ,  C12N15/86

CPC分类号： A61K39/46433 ,  A61K39/4611 ,  A61K39/4631 ,  A61P37/06 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/7158 ,  C07K16/2803 ,  C07K16/2845 ,  C07K16/2887 ,  C07K16/289 ,  C12N15/86 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C12N2740/15043

摘要： This document relates to methods and materials for treating a mammal having an autoimmune disease. For example, materials and methods for producing an immuno-activatable cell comprising a first chimeric antigen receptor and a second chimeric antigen receptor are provided. Methods and materials for treating a mammal having an autoimmune disease comprising administering an immuno-activatable cell are also provided.